Annual Business Report

Overview

The report highlights Valneva's 2018 financial growth, including total revenues of €113.0 million, product sales of €103.5 million and positive EBITDA of €13.1 million. It describes progress in Lyme disease and chikungunya vaccine candidates, including Phase 2 initiation for VLA15 and positive Phase 1 interim results for VLA1553. The company also presents four CSR pillars covering protecting lives, ethical conduct, people and the environment, and states its support for the UN Global Compact.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Condensed report
Fiscal year: 2018
Period: Ends 31 December 2018
Language: English
Pages
File size

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services